checkAd
    Startseite > Aktien > Jaguar Health > Nachrichten
    Jaguar Health Aktie
    0,9521
     
    USD
    -17,92 %
    -0,2079 USD
    Letzter Kurs 08.09.21 NYSE
    0,9501
     
    USD
    1.600 STK
    Geldkurs 08.09.21
    0,9521
     
    USD
    400 STK
    Briefkurs 08.09.21
    ISIN: US47010C4096 · WKN: A2PLYX · USA

    Neueste Nachrichten

    Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
    29.04.24 · Accesswire · Jaguar Health
    Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
    22.04.24 · Accesswire · Jaguar Health
    Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
    18.04.24 · Accesswire · Jaguar Health
    Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
    16.04.24 · Accesswire · Jaguar Health
    Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
    09.04.24 · Accesswire · Jaguar Health
    Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
    08.04.24 · Accesswire · Jaguar Health
    Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
    02.04.24 · Accesswire · Jaguar Health
    Jaguar Health Reports 2023 Financial Results
    01.04.24 · Accesswire · Jaguar Health
    Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
    27.03.24 · Accesswire · Jaguar Health
    GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
    20.03.24 · Accesswire · Jaguar Health
    Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
    23.02.24 · Accesswire · Jaguar Health
    A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
    11.12.23 · Accesswire · Jaguar Health